A Phase I study demonstrates that Avanir Pharmaceuticals' (AVNR) AVP-786 compound has a...

|About: Avanir Pharmaceuticals, Inc (AVNR)|By:, SA News Editor

A Phase I study demonstrates that Avanir Pharmaceuticals' (AVNR) AVP-786 compound has a comparable pharmacokinetic, safety and tolerability profile to the company's AVP-923, which is being trialed for use in patients with Alzheimer's disease, Multiple Sclerosis, Parkinson's and autism. As a results, Avanir believes "AVP-786 would be an ideal candidate to test in one or more of our ongoing clinical programs." (PR)